Health Canada Implements ICH Guideline on Nonclinical Biodistribution Considerations for Gene Therapy Products

• Provides harmonized recommendations for the conduct of nonclinical biodistribution (BD) studies in the development of gene therapy (GT) products;
• Includes recommendations to facilitate the development of GT products while avoiding unnecessary use of animals, in accordance with the 3Rs (reduce/refine/replace) principles;
• Makes recommendations for the overall design of nonclinical BD assessments.

Need to know more about Therapy Products regulation changes? Get in touch with RegASK’s experts.